AR004601A1 - Antagonistas de receptor de aminoacidos - Google Patents

Antagonistas de receptor de aminoacidos

Info

Publication number
AR004601A1
AR004601A1 ARP960105203A ARP960105203A AR004601A1 AR 004601 A1 AR004601 A1 AR 004601A1 AR P960105203 A ARP960105203 A AR P960105203A AR P960105203 A ARP960105203 A AR P960105203A AR 004601 A1 AR004601 A1 AR 004601A1
Authority
AR
Argentina
Prior art keywords
amino acid
receptor antagonists
acid receptor
compounds
modulators
Prior art date
Application number
ARP960105203A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605430.9A external-priority patent/GB9605430D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR004601A1 publication Critical patent/AR004601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se trata de antagonistas de receptores de aminoácidos excitadores, de fórmula (I) en la que X representa un enlace, S,O u NR(2); y R es como se hadefinido en la memoria descriptiva. Dichos compuestos son útiles como moduladores de la función de receptor de glutamato metabotrópico. También sereivindican compuestos intermediarios de aplicación de la preparación de dichos compuestos antagonistas.
ARP960105203A 1995-11-16 1996-11-15 Antagonistas de receptor de aminoacidos AR004601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US687195P 1995-11-16 1995-11-16
GBGB9605430.9A GB9605430D0 (en) 1996-03-15 1996-03-15 Excitatory amino acid receptor antagonists

Publications (1)

Publication Number Publication Date
AR004601A1 true AR004601A1 (es) 1998-12-16

Family

ID=26308934

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960105203A AR004601A1 (es) 1995-11-16 1996-11-15 Antagonistas de receptor de aminoacidos
ARP960105202A AR004600A1 (es) 1995-11-16 1996-11-15 Antagonistas de receptor de aminoacidos excitadores

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960105202A AR004600A1 (es) 1995-11-16 1996-11-15 Antagonistas de receptor de aminoacidos excitadores

Country Status (13)

Country Link
EP (1) EP0774455A1 (es)
JP (1) JP2000500752A (es)
KR (1) KR19990067597A (es)
CN (1) CN1202103A (es)
AR (2) AR004601A1 (es)
AU (1) AU703093B2 (es)
BR (1) BR9611521A (es)
CA (1) CA2237598A1 (es)
CO (1) CO4750811A1 (es)
EA (1) EA000894B1 (es)
TW (1) TW427973B (es)
WO (1) WO1997017950A1 (es)
YU (1) YU60896A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825211B1 (en) 1997-07-18 2004-11-30 Georgetown University Bicyclic metabotropic glutamate receptor ligands
EP1000015A1 (en) * 1997-07-18 2000-05-17 Georgetown University Bicyclic metabotropic glutamate receptor ligands
US6136861A (en) * 1998-03-17 2000-10-24 Pfizer Inc Bicyclo[2.2.1]heptanes and related compounds
EP1396273A1 (en) * 1998-03-17 2004-03-10 Pfizer Products Inc. Bicyclo(2.2.1.)heptanes and related compounds
ES2222715T3 (es) * 1998-08-31 2005-02-01 Taisho Pharmaceutical Co. Ltd. Derivados de 6-fluorobiciclo(3.1.0)hexano.
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
ATE405289T1 (de) 2001-12-27 2008-09-15 Taisho Pharmaceutical Co Ltd 6-fluorobicyclo 3.1.0 hexan-derivate
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
EP2640687B1 (en) 2010-11-18 2018-06-27 Eli Lilly and Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981880A (en) * 1969-03-14 1976-09-21 The Upjohn Company Racemic prostaglandins of the 2-series and analogs thereof
NZ218115A (en) * 1985-11-18 1990-02-26 Shionogi & Co Bicyclic sulphonamides and pharmaceutical compositions
ATE206915T1 (de) * 1994-08-12 2001-11-15 Lilly Co Eli Behandlung von angstzuständen
WO1996004900A1 (en) * 1994-08-12 1996-02-22 Eli Lilly And Company Composition and method for protection against drug dependency
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL

Also Published As

Publication number Publication date
CN1202103A (zh) 1998-12-16
EP0774455A1 (en) 1997-05-21
AU703093B2 (en) 1999-03-18
KR19990067597A (ko) 1999-08-25
YU60896A (sh) 1998-12-23
BR9611521A (pt) 1999-06-29
EA000894B1 (ru) 2000-06-26
CA2237598A1 (en) 1997-05-22
AR004600A1 (es) 1998-12-16
CO4750811A1 (es) 1999-03-31
JP2000500752A (ja) 2000-01-25
WO1997017950A1 (en) 1997-05-22
AU7731096A (en) 1997-06-05
TW427973B (en) 2001-04-01
EA199800380A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
EA199800376A1 (ru) Антагонисты рецепторов возбудительной аминокислоты
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
DE69021618D1 (de) Antagonisten von exzitatorischen Aminosäuren.
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
AU7166787A (en) Antagonists of specific excitatory amino acid neurotransmitter receptors
ATE247481T1 (de) Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
AR004601A1 (es) Antagonistas de receptor de aminoacidos
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
DE68905845D1 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
PT94982A (pt) Processo para a preparacao de peptidos com accao antagonista contra bradiquinina e de composicoes farmaceuticas que os contem
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
TR199701576T1 (xx) N-aril-1,2,4,-triazolin-5-onlar.
EA199800230A1 (ru) Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
IT1276153B1 (it) Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.
ES2139928T3 (es) Antagonistas de receptores de aminoacidos de excitacion.
MX9603199A (es) Antagonistas de receptores a endotelina.
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
DE69617010T2 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
ES2189211T3 (es) Derivados de naftotiazolona activos en el receptor dopaminergico d 3.
MX9803834A (es) Antagonistas de receptores de aminoacidos excitadores.
NO20000518L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
ES2094338T3 (es) Antagonistas de amino-acidos de excitacion.
HUP9900606A2 (hu) 5-HT3 Receptor antagonisták mozgászavar kezelésére

Legal Events

Date Code Title Description
FA Abandonment or withdrawal